<DOC>
	<DOCNO>NCT00492700</DOCNO>
	<brief_summary>This study intend find whether treatment rosiglitazone improve state liver relate blood marker patient nonalcoholic steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>A One-Year , Randomized , Double-Blind , Placebo-Controlled Trial Rosiglitazone Non-Alcoholic Steatohepatitis</brief_title>
	<detailed_description>Phase one : A double blind randomize placebo control trial rosiglitazone - 64 pt biopsy proven NASH randomize receive either rosiglitazone 8 mg/day placebo one year . - one year treatment patient undergo liver biopsy 4 month follow treatment Primary endpoint : improvement least 30 % histological score steatosis Secondary endpoint : improvement ALT value , necrosis inflammation fibrosis Phase II extension open label trial All participant phase one regardless drug receive first year treat rosiglitazone 2 additional year . A liver biopsy perform end two additional year order find whether prolonged rosiglitazone therapy result improvement liver injury NASH patient .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Histologically proven NASH steatosis &gt; = 20 % Increased serum ALT bland steatosis daily alcohol &gt; 20/30 g ( women/men ) cause liver disease secondary NASH include druginduced steatohepatitis treatment insulin glitazones cardiac insufficiency Hb &lt; 10 g/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>steatosis ,</keyword>
	<keyword>fibrosis ,</keyword>
	<keyword>diabetes ,</keyword>
	<keyword>obesity</keyword>
</DOC>